1. Introduction {#s0005}
===============

Recently, a preliminary analysis of a large US cohort of critically ill patients with severe novel SARS-CoV-2 disease (COVID-19) has suggested the benefit of systemic anticoagulation on their mortality \[[@bb0005]\]. Life-threatening COVID-19 is characterized by acute respiratory distress syndrome (ARDS), sepsis, multi-system organ failure, and thromboembolic disease \[[@bb0010]\]. The latter integrates both venous and arterial thromboembolic phenomena; while, the underlying pathophysiology remains poorly understood. The administration of enhanced systemic anticoagulation in patients with severe COVID-19, and Padua prediction score ≥ 4 or D-dimer\>3.0 μg/ml has been previously suggested due to the increased occurrence of pulmonary embolism (PE) \[[@bb0015],[@bb0020]\]. Scarce data exist though about the use and safety of thrombolysis for massive PE in patients with COVID-19. Herein, we are briefly discussing the case of a critically ill COVID-19 patient who underwent thrombolysis for life-threatening PE.

2. Case presentation {#s0010}
====================

A previously healthy 47 year old male was admitted to our emergency department due to severe COVID-19 pneumonia, which was confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR) assays, performed on nasopharyngeal swabs, using QuantiNova Probe RT-PCR kit (Qiagen) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland) \[[@bb0025],[@bb0030]\]. The patient presented with rapidly evolving ARDS \[partial arterial pressure of oxygen to fractional inspired concentration of oxygen (PaO~2~/FiO~2~) ratio: 175\] and sepsis. Laboratory results showed normal coagulation profile, leukocytosis with lymphocytopenia (0.41 × 10^9^/l; normal: 1.1--3.2 × 10^9^/l), increased C-reactive protein (432.5 mg/l; normal: 0--7 mg/l), D-dimer (7.7 μg/ml; normal: 0--0.5 μg/ml), lactate dehydrogenase (1.107 units/l, normal: 100--190 units/l), and ferritin (1.283 ng/ml, normal: 23--336 ng/ml) \[[@bb0010]\]. The electrocardiogram depicted sinus tachycardia 119 b/min without any other abnormalities. A full work-up for other systemic disorders including thrombophilia and antiphospholipid antibodies screening was sent \[[@bb0035]\]. The patient was intubated and transferred to the intensive care unit (ICU). At that time, it was deemed unnecessary to perform a chest computed tomography (CT) scan due to the patient\'s critical state and COVID-19 status. Fig. 1Point-of-care-cardiac ultrasound (day-2) performed on our critically ill patient with COVID-19: modified four-chamber (A), and short-axis at the level of aortic valve (B) views depicting a large free-floating thrombus (white arrows) migrating to the pulmonary circulation along with severe RV dilatation/dysfunction. Also, on day-2, another short axis view (C) shows a D-shaped left ventricle in systole due to right ventricular pressure overload. On day-5 post-thrombolysis, four-chamber view (D) shows restored right ventricular function. Abbreviations: RA = right atrium, RV = right ventricle; LA = left atrium; LV = left ventricle; IVS = interventricular septum, Ao = aorta.Fig. 1

In the ICU (day-1), ARDS-net/prone positioning ventilation, and empiric treatment with ribavirin/ interferon beta-1b, ceftriaxone/azithromycin, dexamethasone, and prophylactic anticoagulation has been administered as per hospital protocol \[[@bb0040]\]. On hospital day-2, the patient developed shock with worsening oxygenation (PaO~2~/FiO~2~: 95), and increasing norepinephrine requirements. Follow-up laboratory examinations revealed a slight increase of troponin-I levels (2.1 ng/ml; normal: \<0.04 ng/ml). Point-of-care-ultrasound (POCUS) revealed a large thrombus migrating from the right atrium to the pulmonary circulation, and acute right ventricular (RV) dilatation and dysfunction ([Fig. 1](#f0005){ref-type="fig"}A, B, C; and [Suppl. Video 1](#ec0005){ref-type="supplementary-material"}). However, lower-limb compression duplex sonography was normal. The dose of norepinephrine was increased, enoxaparin was weight-adjusted to a therapeutic dose (80 mg twice daily), and positive end-expiratory pressure was reduced (from 11 cm H~2~0 to 8 cm H~2~0) to compensate for venous return and RV function. Unfortunately, the patient\'s hemodynamic status and oxygenation did not improve. Therefore, intravenous alteplase (100 mg over 2 h) was administered as rescue therapy. The patient made an uneventful recovery without bleeding complications. On day four post-thrombolysis, he was weaned off vasopressors, and his PaO~2~/FiO~2~ increased to 290. Follow-up POCUS showed no right heart thrombi, and restored right ventricular function five days post-thrombolysis ([Fig. 1](#f0005){ref-type="fig"}D; [Suppl. Video 2](#ec0010){ref-type="supplementary-material"}). He was extubated on day-10. RT-PCR for COVID-19, and microbiology were negative on day-17. The work-up for other systemic disorders including thrombophilia was negative. The patient was discharged to home isolation on hospital day 20 in good clinical condition. Oral Rivaroxaban was prescribed for three months \[[@bb0045]\].

3. Discussion {#s0015}
=============

COVID-19 refractory ARDS may be due to the interplay of inflammatory pathologies targeting both the lung ventilation and perfusion ("dual-hit" pathology). Our patient had increased levels of D-dimer and inflammation biomarkers, and life-threatening thromboembolic disease \[[@bb0005], [@bb0010], [@bb0015], [@bb0020]\]. An increased incidence of thromboembolic phenomena has been previously documented in critically ill COVID-19 patients \[[@bb0050], [@bb0055], [@bb0060]\]. Also, thromboembolic disease is a well-established feature of life-threatening COVID-19 \[[@bb0065], [@bb0070], [@bb0075]\]. Notably, cardiac involvement in COVID-19 includes arrhythmia (atrial fibrillation, ventricular tachyarrhythmia and fibrillation), cardiac injury \[elevated troponin I and creatine kinase levels\], fulminant myocarditis, heart failure, and PE \[[@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110]\]. SARS-CoV-2 could directly bind to the ACE-2 receptors causing diffuse endothelial injury \[[@bb0115]\], which in turn along with the ensuing inflammation may promote hypercoagulable states \[[@bb0005], [@bb0010], [@bb0015], [@bb0020]\].

This case-report, albeit its limitations, illustrates that the administration of enhanced anticoagulation in patients with severe COVID-19, and Padua prediction score ≥ 4 or D-dimer\>3.0 μg/ml may be a necessary critical care practice \[[@bb0015],[@bb0020]\]. Surely, the risk of bleeding should be not underestimated; hence these patients require diligent ICU monitoring \[[@bb0005]\]. Catheter-directed thrombolysis for massive PE in COVID-19 has been previously described in a single case-report \[[@bb0120]\]. This is the first case, to our knowledge, that systemic thrombolysis is administered for life-threatening PE in a COVID-19 patient. No specific guidelines exist for the management of massive PE in COVID-19. Thrombolysis could be an effective and safe therapy for massive PE in mechanically ventilated COVID-19 patients. Also, we underline that POCUS, despite its inherent limitations, could be a flexible diagnostic and management tool in refractory ARDS due to COVID-19 \[[@bb0125]\]. Notably, post-thrombolysis, we have administered a new oral anticoagulant that may be useful in preventing future thromboembolic phenomena as SARS-CoV-2 reinfection and natural immunity remain obscure. However, the putative interaction of anticoagulation therapy with empiric antivirals should be further explored \[[@bb0005],[@bb0015]\]. In conclusion, thrombolysis appeared to be a safe and effective therapy for massive PE in COVID-19 when administered under close ICU monitoring.

The following are the supplementary data related to this article.Suppl. Video 1Point-of-care-cardiac ultrasound modified four-chamber view (day-2) revealing a large thrombus in a dysfunctional right heart "en-route" to the pulmonary circulation in our critically ill COVID-19 patient.Suppl. Video 1 Suppl. Video 2Point-of-care-cardiac ultrasound modified four-chamber view (day-5) depicting no thrombi in the right heart, and normalization of right ventricular function in our critically ill COVID-19 patient.Suppl. Video 2
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